Key facts
- It has raised $100K; the latest was Later Stage VC ($100K) in Jan 2025.
- Notable investors include SOSV, IndieBio, New York Ventures, Small Business Innovation Research and Small Business Technology Transfer Programs, Westchester County Biosciences Accelerator.
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for FREZENT
- ·The full record, as it builds
Funding rounds
No funding rounds for FREZENT are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About FREZENT
Developer of antibody-based therapeutics designed to prevent cancer recurrence by targeting dormant cancer cells. The company offers engineered antibodies and antibody-drug conjugates targeting tumor-specific antigens linked to metabolic reactivation, enabling cancer patients and oncology care providers to achieve longer remission and reduce relapse risk.
- Sector
- Healthcare
- HQ
- New York, NY, United States
- Founded
- 2017
- Employees
- 10
- Website
- frezent.com/
- Ownership
- Privately Held (backing)
FREZENT doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in FREZENT shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on FREZENT in its N-PORT filings yet. We sweep new filings monthly.